Sharemaestro Newsreel

Liquidia earnings in focus as YUTREPIA launch faces patent test

Liquidia Technologies Inc. is reporting its second-quarter results with investors focusing on the commercial success of its new pulmonary hypertension drug, YUTREPIA, and the ongoing patent litigation. Analysts anticipate strong earnings and revenue growth, though the stock's recent surge reflects both high expectations and …

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

The pharmaceutical sector differs from many industries as stock performance often depends less on near-term results and more on the success of products in development. For biotech companies, clinical and regulatory developments can sharply alter valuations by changing expectations for a drug's safety, efficacy …

OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Moody's Ratings has upgraded Teva Pharmaceutical Industries Ltd.'s corporate credit rating to Baa3 from Ba1, achieving investment-grade status with a stable outlook. This upgrade reflects Teva's successful "Pivot to Growth" strategy, including innovative products, an expanded pipeline, and continued debt reduction. The recognition from …

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

BioCryst Pharmaceuticals achieved profitability in 2025 and saw a significant revenue increase in Q2 2026, leading to speculation about its acquisition. Takeda is considered the top potential buyer due to BioCryst's drug navenibart directly threatening Takeda's HAE franchise, with AstraZeneca ranking second. Other potential …

Haleon unit launches tender offer for $2 billion 2027 notes

Haleon US Capital LLC, a wholly owned subsidiary of Haleon plc, has launched a tender offer to purchase all outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027. This tender offer is part of Haleon's strategy to manage and optimize its debt portfolio, …

Haleon offers to buy back $2B of 3.375% notes due 2027 to optimize debt portfolio.

Haleon plc's subsidiary, Haleon US Capital LLC, has launched a tender offer to repurchase up to $1.999 billion of its 3.375% senior notes due in March 2027. This strategic move aims to optimize the company's debt portfolio and enhance financial flexibility, contingent on the …

ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration

ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 25.9% year on year to $266 million. On the other hand, the company's …

InterCure Ltd. (INCR) shareholders back proposal at August 11, 2026 special meeting

Why Is Hims & Hers Health Stock Falling Tuesday?

Wall St set for higher open as investors weigh fresh US-Iran peace deal reports

By Avinash P and Purvi Agarwal Aug 11 (Reuters) - Wall Street's main indexes were poised to open higher on Tuesday as investors welcomed a report suggesting the United States and Iran were close to "some sort ‌of an arrangement" to end six months …

Organigram Global Inc. Q3 Results: Net revenue rises 49% YoY

Organigram Global Inc. reported record Q3 FY26 results, with net revenue increasing by 49% year-over-year to $105.8 million and adjusted EBITDA jumping by 136% to $13.4 million. This significant growth was primarily driven by the acquisition of Sanity Group, which contributed €25 million in …

Earnings call transcript: OrganiGram posts record Q3 2026 revenue as stock rises

OrganiGram Global reported record fiscal Q3 2026 net revenue of CAD 105.8 million and adjusted EBITDA of CAD 13.4 million, driven largely by the consolidation of Sanity Group. The acquisition helped increase international revenue to 35% of total revenue. Despite the strong performance and …

Organigram Global Q3 Earnings Call Highlights

Key Points Interested in Organigram Global Inc.? Here are five stocks we like better. Record Q3 performance: Revenue rose 49% year over year to C$105.8 million and adjusted EBITDA jumped 136% to C$13.4 million, driven largely by the Sanity Group acquisition and improved Canadian …

Update: US Equity Futures Mostly Flat Pre-Bell as US-Iran Stalemate Persists

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, …

Riot, NIQ surge, On Holding tumbles premarket

Investing.com - U.S. stock futures were little changed on Tuesday, as fading hopes for a deal to reopen the Strait of Hormuz kept oil prices elevated, while investors looked ahead to key U.S. inflation data for fresh clues on the Federal Reserve's interest rate …

Hims & Hers' Revenue Growth Comes at a Cost

This article first appeared on GuruFocus. Hims & Hers Health, Inc. (NYSE:HIMS) fell 6.11% in premarket after reporting second-quarter revenue of $753.2 million, up 38% year over year and above the $699 million analysts estimate. The company added 452,000 subscribers during the past year, …

Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes

LONDON, Aug. 11, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that its wholly owned subsidiary, Haleon US Capital LLC (the "Offeror") is offering to buy back any and all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes …

REG - Haleon PLC Haleon US Capital - Cash tender offer - outstanding 2027 3.375% Notes

Haleon plc announced that its subsidiary, Haleon US Capital LLC, is initiating a cash tender offer to buy back all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027. This move aligns with Haleon's capital allocation strategy and aims to optimize …

Zero-Sugar Hi*Ball Energy Drink Will Reach Wolves' Molineux

Tilray Brands announced that its zero-sugar sparkling energy drink, Hi*Ball Energy, has partnered with Wolverhampton Wanderers Football Club as their Official Energy Drink Partner for the 2026/27 English Football League Championship season. This marks Hi*Ball's first UK sports partnership, aiming to expand its presence …

Hims & Hers Raises Outlook as Cash Flow Weakens

This article first appeared on GuruFocus. Hims & Hers Health Inc. (HIMS, Financials) the digital health platform, boosted its full-year revenue outlook after another quarter of robust growth, but investors are also getting a better sense of what that expansion will cost. Warning! GuruFocus …

Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?

It was reported on July 28 that Alkermes plc (NASDAQ:ALKS) sank 5% to $50.05 following its second-quarter 2026 financial report. Despite topping top-line consensus estimates with a 27% year-over-year revenue surge to $496.0 million, profit-taking took hold after a massive year-to-date rally. The second-quarter …

Teva Pharmaceutical Industries Ltd. Receives Moody’s Upgrade to Investment-Grade Baa3 Rating

Moody's has upgraded Teva Pharmaceutical Industries Ltd.'s corporate credit rating to Baa3 from Ba1, achieving an investment-grade status with a stable outlook. This upgrade acknowledges Teva's successful growth strategy, including innovative products and debt reduction, and enhances the company's financial flexibility and investor access. …

United Therapeutics chairperson & CEO sells $5.05m in stock

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (NASDAQ:UTHR), sold 9,500 shares of company stock worth over $5 million on August 7, 2026, after exercising stock options. These transactions were executed under a pre-arranged 10b5-1 trading plan. The article also mentions United …

Curaleaf Announces Intention to Launch Take-Over Bid for Aurora Cannabis to Solidify its Position as the Global Cannabis Industry Leader

Curaleaf Holdings, Inc. announced its intention to launch a take-over bid for Aurora Cannabis Inc. to create the leading global cannabis platform. The proposed offer values Aurora Shares at US$4.00 each, representing a 45% premium over Aurora's 30-day VWAP, and seeks to combine Aurora's …

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

This article lists 12 healthcare stocks experiencing significant movement in pre-market trading on Tuesday. It details the percentage change, stock price, and market capitalization for each company, noting recent earnings reports for some. The list includes both gainers like Mereo BioPharma Group and Organigram …

HC Wainwright Issues Pessimistic Outlook for AMLX Earnings

Organigram Global Raises FY26 Revenue Guidance Above Estimates

Organigram Global has raised its revenue guidance for fiscal year 2026, now expecting to exceed $255.197 million, which is above the prior market estimate of $241.360 million. This upward revision reflects strong operational performance and positive market sentiment within the cannabis sector, indicating robust …

Stocks Mostly Up Pre-Bell as Investors Assess Uncertainty Over US-Iran Deal

wall street stock market flag new york trading equity -Shutterstock US equity markets were mostly trending higher before the open Tuesday as investors weigh fading optimism that the US and Iran would reach a quick resolution to their conflict and reopen the Strait of …

Organigram Global (OGI) posts 49% revenue growth and big Q3 revaluation gain

Organigram Global Inc. (OGI) reported strong Q3 Fiscal 2026 results, with net revenue increasing 49% to $105.8 million, largely driven by the acquisition of Germany-based Sanity Group and higher Canadian recreational sales. The company posted a net income of $105.5 million, primarily due to …

Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026

Incannex Healthcare Inc. announced it has received an additional A$5.1 million R&D Tax Incentive refund, bringing its total non-dilutive capital received in 2026 to over A$11.2 million. This refund strengthens the company's financial position and provides flexibility to advance its clinical pipeline, including key …

Incannex receives A$5.1M final R&D refund, totaling A$11.2M non-dilutive funding

Incannex Healthcare (IXHL) has received a final A$5.1 million R&D tax incentive refund, bringing its total non-dilutive funding for 2026 to over A$11.2 million. This significant capital influx strengthens the company's cash position and debt-free balance sheet, providing financial flexibility to advance key clinical …

Stocks making the biggest moves premarket: Riot Platforms, Hims & Hers Health, Intel & more

Check out the companies making the biggest moves premarket: Intel – The chipmaker fell slightly after upsizing a common stock offering to $20 billion from $15 billion. The proceeds, Intel said, would be used for " general corporate purposes ." Hims & Hers Health …

Hims & Hers Q2 2026 earnings: loss despite revenue beat

Hims & Hers Health reported a net loss of $86.3 million in the second quarter of 2026, swinging from net income of $42.5 million in the same period a year earlier, even as revenue climbed 38% to $753.2 million. The company raised its full-year …

TKNO Looks 52.0% Overvalued on GF Value™

Alpha Teknova Inc (NASDAQ: TKNO) has been upgraded to a Buy rating by BTIG with an $8 price target, following a strong Q2 performance and improved funding in the life sciences sector. Despite this, GuruFocus's GF Value™ metric suggests TKNO is approximately 52.0% overvalued, …